
#ACR23 Late-Breaking Abstr#L10 Phase 2 crossover RCT of Dazodalibep, in #Sjogren pts with low ESSDAI but high ESSPRI. ESSPRI and FACIT-FATIGUE improved in both Stage 1 and also after X-over after 159 days. One to look out for those with high symptoms burden @RheumNow #ACRBest https://t.co/yGGrPmUOHU
Links:
14-11-2023